Fibroblast growth factor 23 and soluble Klotho in patients with autosomal dominant polycystic kidney disease

Nephrology (Carlton). 2017 Nov;22(11):848-853. doi: 10.1111/nep.12862.

Abstract

Aim: This study aimed to examine the roles of fibroblast growth factor 23 (FGF23) and soluble Klotho in phosphate metabolism in autosomal-dominant polycystic kidney disease (ADPKD) patients.

Methods: We measured these two factors and phosphate metabolism parameters in 80 patients with ADPKD and 53 patients with non-diabetic chronic kidney disease (CKD).

Results: The mean serum FGF23 level in the ADPKD group was significantly (twofold) higher than in the non-diabetic CKD patients, but the mean soluble Klotho level in the ADPKD group was significantly lower in the non-diabetic CKD group. The mean serum phosphate levels of the two groups were similar. The estimated glomerular filtration rate (eGFR) was approximately 45 mL/min per 1.73 m2 in both groups, and their serum vitamin D metabolite levels were in the normal range.

Conclusion: The serum FGF23 levels were significantly higher and soluble Klotho levels significantly lower in the ADPKD group than in the non-diabetic CKD group matched for eGFR, and these findings may be associated with resistance of renal phosphate excretion.

Keywords: fibroblast growth factor 23; klotho; parathyroid hormone; phosphate; polycystic kidney disease.

MeSH terms

  • Adult
  • Aged
  • Female
  • Fibroblast Growth Factor-23
  • Fibroblast Growth Factors / blood
  • Fibroblast Growth Factors / physiology*
  • Glomerular Filtration Rate
  • Glucuronidase / blood
  • Glucuronidase / physiology*
  • Humans
  • Klotho Proteins
  • Male
  • Middle Aged
  • Phosphates / metabolism
  • Polycystic Kidney, Autosomal Dominant / blood
  • Polycystic Kidney, Autosomal Dominant / physiopathology*

Substances

  • FGF23 protein, human
  • Phosphates
  • Fibroblast Growth Factors
  • Fibroblast Growth Factor-23
  • Glucuronidase
  • Klotho Proteins